First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).
Elizabeth A. Griffiths
No relevant relationships to disclose
Hagop M. Kantarjian
No relevant relationships to disclose
Gail J. Roboz
No relevant relationships to disclose
Patricia Lamont Kropf
No relevant relationships to disclose
Casey Lee O'Connell
Honoraria - Celgene
Karen W. L. Yee
No relevant relationships to disclose
Guillermo Garcia-Manero
No relevant relationships to disclose
Elias Jabbour
No relevant relationships to disclose
Eric Jay Feldman
No relevant relationships to disclose
Katherine Jean Walsh
No relevant relationships to disclose
David Rizzieri
Consultant or Advisory Role - ARIAD; Celgene; GlaxoSmithKline; Novartis; Pfizer
Honoraria - ARIAD; Celgene; GlaxoSmithKline; Novartis; Teva
Wendy Stock
No relevant relationships to disclose
Scott D. Lunin
No relevant relationships to disclose
Sue Naim
No relevant relationships to disclose
Gavin S. Choy
No relevant relationships to disclose
Pietro Taverna
No relevant relationships to disclose
Yong Hao
No relevant relationships to disclose
Mohammad Azab
No relevant relationships to disclose
Woonbok Chung
No relevant relationships to disclose
Jean-Pierre J. Issa
Consultant or Advisory Role - Janssen